President & CEO / Co-founder
A biotech/pharmaceutical industry leader with over 25 years of experience within pharma and biotech. Dr. Vetticaden has served as a corporate officer for multiple public companies including Interim CEO for Insys Therapeutics and as Chief Medical Officer for Depomed Inc, Cubist Pharmaceuticals, Maxygen Inc., Mast Therapeutics and Insys Therapeutics. He has also held key leadership positions at global pharmas including Johnson & Johnson and Aventis (now Sanofi) where he led the development, in-licensing and acquisition of multiple “blockbuster” products. Dr. Vetticaden holds: an MBA from MIT’s Sloan School of Management, an MD from the University of Maryland with a residency in internal medicine at the Baylor College of Medicine and a PhD in pharmaceutical sciences from Virginia Commonwealth University.
Chief Operating Officer / Co-Founder
A biotech/pharmaceutical industry leader with over 25 years of bio-pharmaceutical industry experience. Dr. Emanuele has served as a senior executive / corporate officer at CytRx Corp., Avanir Pharmaceuticals, Kemia Inc, DaVita Inc, and Mast Therapeutics. He is a listed inventor on numerous patents, been awarded multiple NIH and FDA grants and has played key leadership roles in the approval of novel, first in class therapeutics. He also has extensive corporate partnership experience with a collective deal value > $1.0 billion. His educational background includes a PhD in pharmacology from Loyola University of Chicago and an MBA from the University of Colorado.
Dorota Skowronska-Krawczyk is a biochemist and molecular biologist. She received her MSc in Molecular Biology at the University of Warsaw, Poland, and PhD in Biochemistry at the University of Geneva, Switzerland. Her primary research interest is in gene expression regulation and the impact of global changes in the nuclear organization on cellular programs with a particular emphasis on aging using the eye as a model system. Dr. Skowronska- Krawczyk is the co-inventor of the technology licensed to Visgenx. She is currently Assistant Professor of Ophthalmology, University of California San Diego, Shiley Eye Institute. She has authored a number of publications in high impact factor journals including Nature, Developmental Cell, Molecular Cell, and others. Her research is currently funded by several foundations, grants, and a NIH National Eye Institute R01 Award.
Daniel Chao is a vitreoretinal surgeon, clinician scientist and entrepreneur. He completed his MD and PhD in Neurosciences at Stanford University, ophthalmology residency at Bascom Palmer Eye Institute, vitreoretinal fellowship at University of California San Francisco, and is now on the faculty at the Shiley Eye Institute at UCSD. In addition to treating patients with the full spectrum of retinal diseases, he runs a translational research program focusing on developing new therapeutics and diagnostics in retina, with a special focus on macular degeneration and diabetic retinopathy, and is a coinventor on the technology that has been licensed to Visgenx. He has published over 30 peer reviewed publications. He is an experienced clinical investigator, serving as principal investigator for numerous clinical trials in wet and dry AMD and diabetic retinopathy. He has a special interest in entrepreneurship and innovation, and serves on the scientific advisory board of multiple early stage companies in the therapeutic, device and diagnostic imaging space in retina.
Dr. Douglas is a pharma/biotech industry veteran with more than three decades of experience in healthcare, pharmaceuticals and entrepreneurship. Prominent among his experience were roles as: Executive Vice President and member of the Board of Management of Aventis AG (now Sanofi); Chief Scientific Advisor of Bayer Healthcare AG, and as a BOD member for several biopharmaceutical companies. He has held various academic positions including Assistant Professor of Medicine at the University of Chicago; Professor of the Practice in the MIT Sloan School of Management with similar appointments at the Harvard/MIT division of health sciences. He was the founder and first executive director of the MIT Center for Biomedical Innovation. Dr. Douglas is also President Emeritus for the Austen BioInnovation Institute and is senior partner emeritus of PureTech Ventures. He was a member of the National Center for Advancing Translational Sciences (NCATS) Advisory Council, BioOhio Board of Directors, Governor Kasich’s Ohio Medical Corridor initiative, national chairman of the Value-driven Engineering and U.S. Global Competitiveness initiative, and was a member of the Lehigh University Board of Trustees. Douglas holds a BS in Chemistry from Lehigh University, Ph.D. in Physical Chemistry and M.D. from Cornell University with residency in internal medicine at Johns Hopkins and a fellowship in neuroendocrinology at the National Institutes of Health
Elaine J. Heron, Ph.D. Dr. Heron has over 40 years experience in life sciences. She currently serves on the boards of multiple biopharmaceutical companies including: Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN), Amplyx Pharmaceuticals, Inc., DropWorks, Inc., and Palvella Therapeutics, Inc. Her executive management experience includes roles as Chief Executive Officer at Amplyx Pharmaceuticals, Inc. and Labcyte, Inc. She also held senior executive positions at the Applied Biosystems Group of Applera Corporation, including the position of General Manager and Vice President of Sales and Marketing. Dr Heron is also an active member of Life Science Angels, a prominent angel investor group. Dr. Heron earned her B.S. in chemistry with highest distinction, a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University
Santosh Vetticaden, M.D., Ph.D. (Chairman)
Martin Emanuele, Ph.D.